Change in the treatment of cell culture center-related costs as company-wide expenses
First written in FY2019-Q1. 3 of 4 entries say "Restated". Latest entry: FY2019.
72 other companies' latest entry also says "Restated".
- FY2019RestatedAnnual report
「Because the scale of the business has expanded and its importance in management controls has increased, and because research and development activities relating to the future that do not belong to any existing segment have increased, the company changed the treatment of these costs so that they are included in the adjustment amount as company-wide expenses.」
The company continues to disclose that costs related to the cell culture center have been reclassified for management purposes from the Life Science and Equipment Development business to corporate expenses. - FY2019-Q3RestatedAnnual report
「From the first quarter accounting period, the company reviewed its management classifications from the perspectives of its business development, allocation of management resources and the actual structure of management controls. Since its establishment in April 2016, costs related to the cell culture center had been managed as part of the Life Science and Equipment Development Business. However, because the scale of the business has expanded and its importance in management controls has increased, and because research and development activities relating to the future that do not belong to any existing segment have increased, the company changed the treatment of these costs so that they are included in the adjustment amount as company-wide expenses.」
The company has restated the change in management classification under which cell culture center-related costs are included in the adjustment amount as company-wide expenses. - FY2019-Q2RestatedAnnual report
「From the first quarter accounting period, the company reviewed its management classifications from the perspectives of its business development, allocation of management resources and the actual structure of management controls. Since its establishment in April 2016, costs related to the cell culture center had been managed as part of the Life Science and Equipment Development Business. However, because the scale of the business has expanded and its importance in management controls has increased, and because research and development activities relating to the future that do not belong to any existing segment have increased, the company changed the treatment of these costs so that they are included in the adjustment amount as company-wide expenses.」
The company has restated the change in management classification under which cell culture center-related costs are included in the adjustment amount as company-wide expenses. - FY2019-Q1First statedAnnual report
「The company changed the treatment of these costs so that they are included in the adjustment amount as company-wide expenses.」
Cell culture center-related costs were changed from expenses of the Life Science and Equipment Development Business to company-wide expenses.